Philip is a physician scientist with expertise in cancer biology and precision oncology. He trained as a clinical hematologist at Imperial College, London, where he developed specialist knowledge around the laboratory diagnosis and treatment of hematological cancers. He was awarded a PhD by the University of Cambridge based on work investigating genotype-phenotype correlations and genomic mechanisms of disease progression in hematological cancers. Following a year as a Clinical Lecturer in Cambridge, Philip spent 4 years at the BC Cancer Agency in Vancouver, where his research focused on the development of cellular models to study how leukemia is initiated and propagated in human blood cells. He subsequently spent 2 years leading clinical and scientific operations at a biotech start-up founded by leading academics at the Sanger Institute, UK, with the aim of developing methodologies for the interrogation of cancer genomics to inform individual patients’ clinical pathways. Philip continues to contribute to projects at the Sanger Institute as a Visiting Scientist.